Proposal to Remove Nicotine from Poisons List in Malaysia

Mar.29.2023
Proposal to Remove Nicotine from Poisons List in Malaysia
Malaysia's Poison Board considers removing nicotine from Poisons Act, allowing legal sale of e-cigarettes. Concerns raised over lack of regulation.

On March 28th, multiple Malaysian media outlets reported that the Poisons Board of Malaysia would hold a meeting to discuss removing nicotine from the Poisons Act. If this amendment were to pass, it would allow for the legal sale of electronic cigarettes to anyone in Malaysia.


Lift Restrictions on Nicotine


According to Malaysia's Poison Act of 1952, nicotine is classified as a Group C poison, which means that the substance can only be dispensed by a doctor or pharmacist.


According to the Medication Services website of the Ministry of Health in Malaysia, the Poisonous Substances Committee, responsible for the "List of Poisons", will provide professional advice to the Minister of Health on the issue of removing "nicotine".


Dr. Muruga Raj Rajathurai| Source: The Straits Times


This news immediately caught the attention of the medical community. Dr. Muruga Raj Rajathurai of the Malaysian Medical Association (MMA) noted that the association was aware of the removal of nicotine from the controlled substance list under the Poison Act.


They claim that the government's modification of the "poison list" is to enable them to levy taxes on electronic cigarette products containing said substance.


Dr. Muruga continues to state that if this were done before the passage of the Tobacco Control Bill, it would lead to a lack of control over the sales of electronic cigarettes.


He stated that "we are concerned that this move will lead to a significant increase in the sale of electronic cigarettes containing nicotine in public places, with no restrictions on minors.


There are signs of lifting restrictions.


Malaysian Prime Minister Anwar Ibrahim | Source: New Straits Times


Malaysian Prime Minister Anwar Ibrahim announced during his budget speech in February 2023 that the government plans to impose a consumption tax on electronic cigarettes or e-liquids containing nicotine, according to previous reports by 2FIRSTS.


The government had previously estimated the local e-cigarette industry to be worth over RM2 billion (approximately RMB3.13 billion) and planned to allocate half of the tax revenue to the Ministry of Health.


Dr. Muruga states that "according to the 2023 budget proposal, electronic cigarettes containing nicotine will be taxed, but this move appears to be a legalization of their sale in the public domain.


He added that in order to allow the sale of electronic cigarettes containing nicotine, the government must remove nicotine from the controlled substance list of the "Poison Act". Dr. Murugabo explained that so far, there are no appropriate regulations for the use of electronic cigarettes.


In fact, the highly anticipated Malaysian "2022 Tobacco Control and Smoking Bill" was not included in the parliamentary proceedings for the day.


The proposed legislation aims to ban the use of tobacco and electronic cigarette products by anyone born in 2007, known as the "Ultimate Generation Plan" (GEG).


The use of underage individuals has become a focal point.


It is worth noting that currently in Malaysia, the Control of Tobacco Product Regulations (CTPR) only applies to the sale of cigarettes, which mandates that the minimum age to purchase is 18 years old.


Dr. Muruga, stated that removing nicotine from the list would allow both nicotine and non-nicotine electronic cigarettes to be sold openly and legally to anyone, including children.


He said, "Nicotine is addictive, which is why we only allow people over the age of 18 to purchase cigarettes.


Dr. Muruga believes that this latest development indicates that the government is more concerned about potential tax revenue and has almost no consideration for the health impact on Malaysians.


Meanwhile, the Malaysian Pharmaceutical Society (MPS) has strongly opposed the removal of liquid or gel nicotine from the controlled substances list, according to a statement.


Professor Amrahi Buang | Source: BERNAMA


Professor Amrahi Buang, the president of MPS, has expressed concerns that this move could compromise the health and safety of Malaysians.


Amrashi calls on the government to refuse to remove nicotine from the "Poison Law" and to protect public health and safety.


He said: "We urge the government to strengthen regulation around e-cigarettes, including restrictions on marketing and advertising, and to enhance public education on the risks before considering the proposal.


If the amendment to the Poison Control Law is passed, it is expected that the law will be implemented as early as the first week of April.


Related report:


The Malaysian Quit Smoking Society has urged for the establishment of an independent committee to reassess the potential of electronic cigarettes in reducing smoking rates.


Malaysia's E-cigarette Retail Association is urging the government to set a reasonable tax rate as it plans to levy a tax of MYR 1.56 billion on e-cigarettes.


References:


Medical associations are voicing their opposition to a proposal that suggests removing nicotine from the list of poisons. The idea has created controversy and concern amongst healthcare professionals.


Health professionals, including doctors and pharmacists, have criticized the proposed deregulation of nicotine without implementing proper control over vaping products.



Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

Inside Nicotine-Pouch M&A Through Imperial's Yoik Deal: Latham, KPMG, PwC, Goldman Sachs and Morgan Stanley Form the Adviser Lineup
Inside Nicotine-Pouch M&A Through Imperial's Yoik Deal: Latham, KPMG, PwC, Goldman Sachs and Morgan Stanley Form the Adviser Lineup
Imperial Brands' acquisition of Swedish Helwit owner Yoik Group AB has highlighted the professional-services firms supporting cross-border oral nicotine M&A. Latham & Watkins and KPMG advised Imperial, while PwC and TM & Partners advised Yoik. KPMG also appeared on Imperial's acquisition of Black Buffalo earlier in 2026, while PwC played an extensive role in KT&G's acquisition of Swedish nicotine-pouch company Another Snus Factory. Imperial's public disclosures put the global modern oral nicotine delivery market at approximately £8.8 billion in retail sales and 23.5 billion pouches in 2024
Sep.20
Couche-Tard Posts Double-Digit U.S. Same-Store Growth in Other Nicotine Products, Led by Pouches
Couche-Tard Posts Double-Digit U.S. Same-Store Growth in Other Nicotine Products, Led by Pouches
Alimentation Couche-Tard said U.S. same-store sales in its “other nicotine products” category grew at a double-digit rate in the first quarter of fiscal 2027, led by nicotine pouches, while overall U.S. same-store merchandise revenues increased 1.7%. The company also said its Canadian nicotine business continued to face regulatory pressure and illicit-market headwinds. The U.S. performance coincides with Couche-Tard's participation in efforts to reopen Canadian convenience-store access to authorized nicotine pouches, though the company has not established a direct causal link between the two.
Sep.14
IQOS Enters Kantar BrandZ Global Top 100 for First Time, Valued at $36.6 Billion and Ranked No. 74
IQOS Enters Kantar BrandZ Global Top 100 for First Time, Valued at $36.6 Billion and Ranked No. 74
Philip Morris International’s IQOS has entered the Kantar BrandZ Top 100 Most Valuable Global Brands for the first time, ranking No. 74 with a brand value of $36.634 billion and becoming one of only three newcomers to the 2026 ranking. Kantar said the combined value of the Global Top 100 reached $13.1 trillion, up 22% year on year, while the threshold for entry rose to a record high. PMI says IQOS has more than 35 million users worldwide and surpassed $10 billion in annual net revenues within a decade of launch.
Sep.03
Product | FOGER Introduces Switch Pro 30K Nixodine Pod in U.S. Retail, Bringing 6-MN Related Formulation to High-Capacity Pod Platform
Product | FOGER Introduces Switch Pro 30K Nixodine Pod in U.S. Retail, Bringing 6-MN Related Formulation to High-Capacity Pod Platform
FOGER has introduced the Switch Pro 30K Nixodine Pod in U.S. retail channels, bringing a 6-methylnicotine (6-MN)-related formulation into its reusable Switch Pro 30K pod ecosystem. The product retains the existing reusable dock and magnetic replacement pod architecture, featuring a 19ml prefilled pod, dual-mesh heating and Normal/Boost modes. The Nixodine version is labeled nicotine-free in terms of conventional nicotine but uses a 5% Nixodine-related formulation. The product has appeared in U.S. retail and wholesale channels, with some listings indicating Kentucky-only availability.
Aug.28
STIIIZY Redesign Fails to Escape PAX Labs Patent Import Ban as Section 337 Case Also Involves China ALD
STIIIZY Redesign Fails to Escape PAX Labs Patent Import Ban as Section 337 Case Also Involves China ALD
U.S. Customs and Border Protection ruled that STIIIZY had not shown that the redesigned cannabis-vape products covered by its latest request fall outside an ITC limited exclusion order tied to PAX Labs patents. CBP accepted some of STIIIZY’s claim-construction and non-infringement arguments, but the company did not address two additional claims in the same patent. Earlier STIIIZY redesigned cartridges and certain associated components imported with them had received separate CBP clearance.
Sep.16
PMI CEO Attends Opening of IQOS Global Flagship in Tokyo’s Ginza as 1,814 Limited ILUMA i PRIME Sets Launch
PMI CEO Attends Opening of IQOS Global Flagship in Tokyo’s Ginza as 1,814 Limited ILUMA i PRIME Sets Launch
IQOS opened its first global flagship, IQOS Flagship Ginza, in Tokyo on September 4, 2026, replacing the former IQOS Store Ginza after nearly a decade of operation. The new location expands conventional product retail into member lounges, digital experiences, art installations and brand programming. IQOS also launched a Ginza-exclusive IQOS ILUMA i PRIME set limited to 1,814 individually numbered units, priced at JPY11,980, or about US$77. PMI Sales Strategy Consultant Yuji M. later said on LinkedIn that more than 500 people had lined up from the night before the opening.
Sep.07